Health
STAT+: Merck, Isomorphic Labs partner to develop oncology drug candidates
Publication: STAT
Author: Katherine MacPhail
Source published: 19/11/2026, 11:45:00 UTC
Briefing created: 19/11/2026, 13:16:28 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 19/11/2026, 12:21:24 UTC.
Briefings
Merck and Isomorphic Labs announced a research collaboration to develop oncology drug candidates using Isomorphic's AI-driven molecular modeling technology. Merck will manage preclinical, clinical, and commercialization efforts for any resulting products. The partnership combines Merck's proprietary wet lab data with Isomorphic's proprietary drug design engine. The specific target remains undisclosed, described only as having strategic importance.
Key points
- Merck and Isomorphic Labs entered a research collaboration to discover small molecule candidates for an undisclosed oncology target of strategic importance.
- Merck will handle preclinical, clinical, manufacturing, and commercialization of any products developed through this partnership.
Context
This is the latest partnership between a pharma giant and Isomorphic Labs, following previous deals. The collaboration combines Merck's wet lab data with Isomorphic's AI drug design engine to accelerate oncology discovery.
Limitations
The specific oncology target is undisclosed. The partnership covers only research collaboration; no specific products, clinical trial dates, or patient outcomes are mentioned in the source.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 19/11/2026, 13:16:28 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeif6rp2zbr4yu2jcr2zoe4wtdpxu3ucoki3pdklpxyxk7tg72wn2le